

RESEARCH ARTICLE

Lipidomic analysis of immune activation in equine leptospirosis and *Leptospira*-vaccinated horses

Paul L. Wood^{1*}, Margaret Steinman², Erdal Erol², Craig Carter², Undine Christmann³, Ashutosh Verma^{3*}

1 Metabolomics Unit, College of Veterinary Medicine, Lincoln Memorial University, Harrogate, Tennessee, United States of America, **2** Veterinary Diagnostic Laboratory, University of Kentucky, Lexington, Kentucky, United States of America, **3** Center for Infectious, Zoonotic and Vector-borne Diseases, College of Veterinary Medicine, Lincoln Memorial University, Harrogate, Tennessee, United States of America

* paul.wood@lmunet.edu (PLW); ashutosh.verma@lmunet.edu (AV)



OPEN ACCESS

Citation: Wood PL, Steinman M, Erol E, Carter C, Christmann U, Verma A (2018) Lipidomic analysis of immune activation in equine leptospirosis and *Leptospira*-vaccinated horses. PLoS ONE 13(2): e0193424. <https://doi.org/10.1371/journal.pone.0193424>

Editor: Yung-Fu Chang, Cornell University, UNITED STATES

Received: September 2, 2017

Accepted: February 9, 2018

Published: February 23, 2018

Copyright: © 2018 Wood et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data are available in a Supplementary Table.

Funding: Funds for this work were provided by LMU-College of Veterinary Medicine's internal grant program. The funders had no role in the study design or this manuscript.

Competing interests: All authors have no competing interests.

Abstract

Currently available diagnostic assays for leptospirosis cannot differentiate vaccine from infection serum antibody. Several leptospiral proteins that are upregulated during infection have been described, but their utility as a diagnostic marker is still unclear. In this study, we undertook a lipidomics approach to determine if there are any differences in the serum lipid profiles of horses naturally infected with pathogenic *Leptospira* spp. and horses vaccinated against a commercially available bacterin. Utilizing a high-resolution mass spectrometry serum lipidomics analytical platform, we demonstrate that cyclic phosphatidic acids, diacylglycerols, and hydroperoxide oxidation products of choline plasmalogens are elevated in the serum of naturally infected as well as vaccinated horses. Other lipids of interest were triacylglycerols that were only elevated in the serum of infected horses and sphingomyelins that were increased only in the serum of vaccinated horses. This is the first report looking at the equine serum lipidome during leptospiral infection and vaccination.

Introduction

Leptospirosis is a worldwide zoonotic disease that affects horses and many other mammalian species, including man [1]. *Leptospira interrogans* serovar Pomona is commonly associated with clinical leptospirosis in horses in the United States [2, 3] The disease in horses is mainly characterized by spontaneous abortions and recurrent uveitis, with leptospiral abortions occurring late in gestation, typically without any prior clinical signs [4]. Infected mares shed leptospires in the urine for up to 14 weeks and can potentially be a source of infection to other animals. Recurrent uveitis is an important sequela to leptospiral infection and a major cause of blindness in horses [5]. A leptospiral serosurveillance conducted in 2012, reported a prevalence of 45% among horse population in 29 states of the United States and a Canadian province [6].

The microscopic agglutination test (MAT) is the gold standard in serodiagnosis of leptospirosis. The MAT is performed by mixing serial dilutions of patient serum with a battery of live *Leptospira* serovars, and the presence of leptospiral antibodies in the serum is detected by dark-field microscopic examination for agglutination [7]. Among several obvious limitations to the MAT is the test's inability to distinguish between leptospiral antibodies generated as a result of natural infection from that by vaccination. Vaccinated horses have antibodies to leptospiral bacterin and give positive agglutination reactions in MAT. A test that overcomes the technical limitations of the MAT and distinguishes between infected and vaccinated horses would improve the diagnosis of equine leptospirosis. Recent advances in leptospiral research has resulted in identification of a number of immunogenic leptospiral proteins that are either exclusively expressed or significantly upregulated during infection in horses, but their usefulness in differentiating infected and vaccinated horses is still under investigation [8, 9, 10]. As a result, there currently are no diagnostic tests to differentiate these two immune responses. Alterations in lipid metabolism due to pathogen-induced immune activation have previously been reported [11, 12, 13, 14, 15]. In this study, we asked if differences in host's responses to live, multiplying *Leptospira* versus killed leptospirae, present in the vaccine, are reflected in the serum lipidome of these two groups of horses. To that end, we used a non-targeted lipidomics approach to compare serum lipidome of horses with leptospiral infection and horses vaccinated with a commercially available bacterin.

Materials and methods

Serum samples

Fifteen serum samples each from these three groups of horses were used in the study: (1) unvaccinated, naturally infected (Microscopic agglutination test (MAT)-positive) horses, (2) horses vaccinated with Lepto EQ Innovator (Zoetis Inc., Kalamazoo, MI), and (3) unvaccinated, unexposed (MAT-negative) horses (Table 1). Initial screening was performed by MAT, following OIE protocol (http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.01.12_LEPTO.pdf). Naturally infected horses were never vaccinated and had a MAT titer of

Table 1. MAT titers of the serum samples used in the study.

Control sera	MAT titer	Vaccinated sera	MAT titer	Infected sera	MAT titer
UV1	Neg	LV1	1:800 (P, G)	LE1	1:3200 (P)
UV2	Neg	LV2	1:1600 (P); 1:800 (G)	LE2	1:800 (P)
UV3	Neg	LV3	1:3200 (P); 1:100 (G)	LE3	1:400 (P)
UV4	Neg	LV4	1:3200 (P); 1:800 (G)	LE4	1:400 (P)
UV5	Neg	LV5	1:400 (P); 1:100 (G)	LE5	1:800 (P)
UV6	Neg	LV6	1:800 (P); 1:200 (G)	LE6	1:1600 (P)
UV7	Neg	LV7	Neg (P, G)	LE7	1:400 (I)
UV8	Neg	LV8	1:400 (P, G)	LE8	1:200 (I)
UV9	Neg	LV9	1:100 (P, G)	LE9	1:200 (I)
UV10	Neg	LV10	1:200 (G)	LE10	1:12800 (P)
UV11	Neg	LV11	1:100 (G)	LE11	1:3200 (G)
UV12	Neg	LV12	1:800 (P); 1:200 (G)	LE12	1:6400 (P); 1:100 (G)
UV13	Neg	LV13	1:200 (P); 1:100 (G)	LE13	1:25600 (P); 1:400 (G)
UV14	Neg	LV14	1:200 (P)	LE14	1:200 (P); 1:3200 (G)
UV15	Neg	LV15	1:6400 (P); 1:3200 (G)	LE15	1:1600 (P)

MAT, microscopic agglutination test; P, serovar Pomona; G, serovar Grippotyphosa; I, serovar Icterohaemorrhagiae.

<https://doi.org/10.1371/journal.pone.0193424.t001>

1:200 or higher (Table 1). Horses in the vaccinated group did not have a history of prior exposure to *Leptospira* spp. but ruling out any prior exposure is not possible. The control group horses were never vaccinated and had no known history of a prior exposure.

All vaccinated and six of the fifteen samples in the infected group were sent to the UKVDL for MAT titers. Remaining nine samples in the infected group were collected from two different farms in Virginia and Kentucky. Five milliliters of blood was obtained from the jugular vein of horses using a vacutainer needle (20G, 1.5"), a sleeve, and a 10 ml dry blood collection tube (red top). Clotted blood samples were centrifuged at 2,000 x g for 15 minutes. Serum was separated, stored frozen at -20°C, and when required, shipped on dry ice. None of the samples were thawed more than 2 times before the lipidomic analyses were done.

The samples used in this study were left-over aliquots of either clinical diagnostic samples (University of Kentucky Veterinary Diagnostic Laboratory) or blood samples collected in a phlebotomy teaching lab. The phlebotomy lab protocol was approved by the Lincoln Memorial University's Institutional Animal Care and Use Committee.

Lipid extraction and analysis

For the lipid extraction, 100 µL of serum were vortexed with 1 mL of methanol containing stable isotope internal standards ($[^2\text{H}_4]$ DHA, $[^2\text{H}_4]$ hexacosanoic acid, $[^2\text{H}_7]$ cholesterol sulfate, $[^2\text{H}_5]$ MAG 18:1, $[^{13}\text{C}_3]$ DAG 36:2, $[^2\text{H}_{31}]$ PtdE 34:1, $[^2\text{H}_{54}]$ PtdE 28:0, $[^2\text{H}_{31}]$ PtdC 34:1, $[^2\text{H}_{54}]$ PtdC 28:0 and bromocriptine [16–18]. Next 1 mL of water and 2 mL of methyl-tert-butyl ether were added and the tubes were vigorously shaken at room temperature for 30 min. The tubes were next centrifuged at 5,000 xg for 15 min at room temperature and 1 mL of the upper organic extracts was dried by centrifugal vacuum evaporation and dissolved in isopropanol:methanol:chloroform (4:2:1) containing 7 mM ammonium acetate. Constant infusion lipidomics were performed utilizing high-resolution (140,000 at 200 amu) data acquisition, with sub-millimass accuracy on an orbitrap mass spectrometer (Thermo Q Exactive) with successive switching between polarity modes.

In negative ion ESI, the anions of ethanolamine plasmalogens (PlsE), phosphatidylethanolamines (PtdE), lysophosphoethanolamines (LPE), phosphatidylglycerols (PG), phosphatidic acids (PA), lysophosphatidic acids (LPA), cyclic phosphatidic acids (cPA), phosphatidylinositols (PI), ceramides, phosphatidylserines (PS) were quantitated and lipid identities validated by MS/MS.

In positive ion ESI, the cations of choline plasmalogens (PlsC), hydroperoxy PlsCs, phosphatidylcholines (PtdC), lysophosphocholines (LPC), sphingomyelins (SM), monoacylglycerols (MG), and acylcarnitines (ACar), and the ammonium adducts of diacylglycerols (DG), triacylglycerols (TG), and cholesterol esters (CE) were quantitated and lipid identities validated by MS/MS. In the case of hydroperoxy PlsCs, structural identities were validated by the loss of H_2O_2 with MS^2 and generation of a major fragment for choline phosphate.

The cations and anions of bromocriptine were used to monitor for potential mass axis drift. Between injections, the transfer line was washed with successive 500 µL washes of methanol and hexane/ethyl acetate/chloroform (3:2:1) to minimize potential ghost effects.

Statistical analysis

R values (ratio of endogenous lipid peak area to the peak area of an appropriate internal standard) per 100 µL of serum were calculated. Data are presented as mean \pm SEM. Data were analyzed by ANOVA followed by the Dunnett's test to compare the vaccinated and infected groups to the controls. Individual data values are available in the Supplementary Information (S1 Table)




Fig 1. Equine serum levels of cyclic phosphatidic acid 16:0 (cPA) in a pilot study (N = 6 per group) and a validation study (N = 15 per group). Con: controls; Vacc: vaccinated; Infect: infected. *, p < 0.01. R = ratio of the ion intensity for the endogenous cPA to the ion intensity of the stable isotope internal standard.

<https://doi.org/10.1371/journal.pone.0193424.g001>

Results

Cyclic phosphatidic acids (cPA)

cPA 16:0 (Fig 1) was elevated in the serum of both the vaccinated and infected equine groups. Tandem mass spectrometry validated the structure of cPA 16:0, with the anions for 16:0 and glycerophosphate (-H₂O) being monitored with 1.2 and 0.98 ppm mass errors, respectively (Table 2). Other cyclic phosphatidic acids also were elevated in the serum of both the vaccinated and infected groups. These included cPA 18:0, cPA 18:1, and cPA 18:2 (Fig 2). The structures were validated by MS² with the product anions for glycerophosphate (-H₂O) monitored for all 3 cPAs and the respective fatty acid constituents 18:0, 18:1, and 18:2 monitored (Table 2). These data clearly demonstrate that the Th1-type immune responses initiated by leptospirosis [19] or by vaccination [20, 21] result in the generation of cPAs and that these may be important as indicators of immune activation. Of particular interest, horse LV7, while vaccinated, did not demonstrate a MAT titer (Table 1). In contrast cPA changes similar to other

Table 2. Molecular anions of cyclic phosphatidic acids (cPA) and the associated products monitored with tandem mass spectrometry.

cPA	Calc. Anion	Obs. ppm ¹	Calc [Fatty acid] ⁻	Obs ppm ²	Calc [GP-H ₂ O] ⁻	Obs ppm ³
16:0	391.2255	2.4	255.2329	1.2	152.9958	0.98
18:0	419.2568	2.1	283.2637	2.2	152.9958	0.98
18:1	417.2411	2.1	281.2480	2.5	152.9958	1.0
18:2	415.2255	2.0	279.2324	2.1	152.9958	.098

Cal., calculated;

¹, observed cPA parts per million mass error;

², observed MS² product [fatty acid substituent] parts per million mass error;

³, observed MS² product [glycerophosphocholine -H₂O]⁻ parts per million mass error.

<https://doi.org/10.1371/journal.pone.0193424.t002>




Fig 2. Equine serum levels of cyclic phosphatidic acids (cPA 16:0, cPA 18:0, cPA 18:1, and cPA 18:2) and lysophosphatidylcholines (LPC16:0, LPC 18:0, LPC 18:1, and LPC 18:2) in the validation study (N = 15 per group). Con: controls; Vacc: vaccinated; Infect: infected. *, p < 0.01 vs. controls; #, p < 0.01 vs. the vaccinated cohort. R = ratio of the ion intensity for the endogenous cPA or LPC to the ion intensity of the stable isotope internal standard.

<https://doi.org/10.1371/journal.pone.0193424.g002>

vaccinated horses were detected, indicating that this lipid is a more sensitive indicator of immune activation.

Cyclic phosphatidic acids are generated by phospholipase D-dependent transphosphatidylation of lysophosphatidylcholines [22], which are generated by phospholipase A2 hydrolysis of phosphatidylcholines [23] (Fig 3). In parallel with augmented cPAs, we monitored increased




Fig 3. Biosynthetic pathway for cyclic phosphatidic acids (cPA). LPC: lysophosphatidyl-choline; PLA2: phospholipase A2; PLD: phospholipase D; PtdC: phosphatidylcholine. ppm, parts per million mass error.

<https://doi.org/10.1371/journal.pone.0193424.g003>

serum levels of the associated lysophosphatidylcholine (LPC) precursors (Fig 3), albeit, the increases in LPC levels were greater in vaccinated compared to infected horses ($p < 0.01$).

Neutral lipids

Diacylglycerols (DAG) also were elevated in the serum of both vaccinated and infected horses. These included DAG 34:1, DAG 34:2, DAG 34:3, DAG 36:1, DAG 36:2 (Fig 4), DAG 36:3, DAG 36:4, and DAG 36:5. Of particular interest, horse LV7, while vaccinated, did not demonstrate a MAT titer (Table 1). In contrast DAG changes similar to other vaccinated horses were detected, indicating that this lipid is a more sensitive indicator of immune activation.

In contrast, triacylglycerols were only increased in the serum of infected horses. These included TAG 48:1, TAG 48:2, TAG 48:3, TAG 50:1, TAG 50:2, TAG 50:3, TAG 50:4 (Fig 4), TAG 50:5, TAG 52:1, TAG 52:2, TAG 52:3, and TAG 52:4.




Fig 4. Equine serum levels of diacylglycerol 36:2 (DAG 36:2) and triacylglycerol 50:4 (TAG 50:4) in a pilot study (N = 6 per group) and a validation study (N = 15 per group). Con: controls; Vacc: vaccinated; Infect: infected. *, $p < 0.01$. R = ratio of the ion intensity for the endogenous TAG to the ion intensity of the stable isotope internal standard.

<https://doi.org/10.1371/journal.pone.0193424.g004>

Sphingomyelins (SM)

From evaluations of sphingolipids we noted that sphingomyelins were selectively elevated in the serum of vaccinated horses. These included SM d18:1/18:3, SM d18:1/20:0, SM d18:1/22:1, SM d18:1/22:3, SM d18:1/24:0 (Fig 5), SM d18:1/24:1, SM d18:1/24:2 (Fig 5), and SM d18:1/24:3. In contrast SM changes similar to other vaccinated horses were detected, indicating that this lipid is a more sensitive indicator of immune activation.





Fig 5. Equine serum levels of sphingomyelins (SM), SM d18:1/24:0 and SM d18:1:24:2 in a pilot study (N = 6 per group) and a validation study (N = 15 per group). Con: controls; Vacc: vaccinated; Infect: infected. *, $p < 0.01$. R = ratio of the ion intensity for the endogenous SM to the ion intensity of the stable isotope internal standard.

<https://doi.org/10.1371/journal.pone.0193424.g005>

While infections generally result in the induction of serine palmitoyltransferase and thereby augmentation of sphingomyelin synthesis [11], this is not universally noted.

Hydroperoxy glycerophospholipids

The hydroperoxy oxidation products of a number of choline plasmalogens possessing unsaturated fatty acid substituents were detected in infected and vaccinated horses but were greater




Fig 6. Equine serum levels of choline plasmalogen (PlsC) hydroperoxides (N = 15 per group). Con: controls; Vacc: vaccinated; Infect: infected. *, p < 0.01; **, p < 0.05. R = ratio of the ion intensity for the endogenous hydroperoxide to the ion intensity of the stable isotope internal standard.

<https://doi.org/10.1371/journal.pone.0193424.g006>

in the vaccination group (Fig 6). The identities of these oxidation products were validated via tandem mass spectrometry. Using this approach we monitored the loss of both H₂O and H₂O₂ (Table 3) and the generation of choline phosphate (184.0739; < 1 ppm mass error), hallmark features for this class of oxidized lipids [24, 25].

Discussion

There is an ever increasing knowledge base regarding the biochemistry of the immune response during infections and inflammatory diseases. A shift in the Th1 and Th2 responses generally results in up-regulation of Th2-type pro-inflammatory cytokines with bacterial infections [26, 27], viral infections [28, 29], and parasitic invasions [30]. In addition local immune responses, such as in the lung [31], brain [32], and the intestine in inflammatory bowel disease (Crohn’s Disease and Ulcerative Colitis) [33] elicit alterations in the Th1 and Th2 cytokine responses. Pro-inflammatory cytokines act to induce indoleamine-2,3-dioxygenase-1 thereby acting to deplete tryptophan and generate kynurenine. As a result of this activated pathway,

Table 3. Molecular anions observed for the hydroperoxy oxidation products of serum choline plasmalogens (PlsC) and their associated MS² products.

Hydroperoxy Lipid	Calc. Anion	Obs. ppm ¹	Calc [M-H ₂ O] ⁻	Obs ppm ²	Calc [M-H ₂ O ₂] ⁻	Obs ppm ³
PlsC 34:2	774.5643	0.81	756.5537	0.26	740.5588	2.4
PlsC 36:2	802.5956	0.38	784.5850	0.37	768.5901	1.8
PlsC 36:4	798.5643	1.3	780.5537	0.52	764.5588	2.3
PlsC 38:6	822.5643	1.9	804.5537	0.61	788.5588	2.4

Cal., calculated,

¹, observed hydroperoxy lipid parts per million mass error;

², observed MS² product [M-H₂O]⁻ parts per million mass error;

³, observed MS² product [M-H₂O₂]⁻ parts per million mass error.

<https://doi.org/10.1371/journal.pone.0193424.t003>

the kynurenine/tryptophan ratio is often used as a surrogate biomarker of immune activation [34, 35].

Lipid metabolism is also altered by the acute phase reactant response. For example, elevated levels of circulating triglycerides have been observed experimentally with cytokine and lipopolysaccharide injections [11,12, 36], as a result of augmented hepatic lipogenesis. Elevated triglycerides have also consistently been reported with bacterial [11,12,13] and parasitic infections [14, 15]. Altered sphingomyelin metabolism has also been reported, with increases in pneumonia patients [37] and decreases in HIV patients [38].

To further evaluate alterations in the serum lipidome during immune activation we took advantage of the opportunity to compare the serum lipidome of horses with active leptospirosis infection [1, 4, 39] and horses vaccinated with a commercial bacterin [40, 41]. Our results show that serum levels of cyclic phosphatidic acids (cPA), diacylglycerols, and hydroperoxide oxidation products of choline plasmalogens were elevated in both vaccinated and naturally infected horses. Perhaps more importantly, we observed that triacylglycerols were only elevated in the serum of infected horses and sphingomyelins were increased only in the serum of vaccinated horses.

In previous and ongoing studies in our lab we have demonstrated increased levels of cPAs in airway surfactant of horses with asthma [42]. Phospholipase A2 [43, 44] and PLD [45, 46] are both augmented during the early phase of infections suggesting that our cPA biomarkers may be simple biochemical readouts of the induction of these enzymes by immune activation (see Fig 3). Of particular note is that our data is the first to demonstrate that vaccination can activate the same enzyme systems. These data suggest that cPAs may be useful as global biomarkers of immune activation during various infections in horses and possibly other animal species. Considering the breadth of bioactivities of this class of lipids [47], their contributions to immune responses may be diverse, particularly since they modulate nuclear function [48,49]. In this regard, pharmacological studies have shown that cPA analogs potentially reverse experimental osteoarthritis [50], block immune-induced demyelination [51], and inhibit the growth of cancer cells [52].

Plasmalogens are essential membrane lipids, particularly in lipid rafts [23]. Alterations in these structural glycerophospholipids, induced by lipid oxidation, may play a role in the host's immune response, particularly in the development of immunity as evidenced by the dramatic increases in circulating hydroperoxy choline plasmalogens in the *Leptospira*-vaccinated animals. The roles of singlet oxygen-oxidation, free radicals and/or oxygenases in the production of these lipids with vaccination remain to be defined.

In this study we demonstrated that triacylglycerols (TAGs) are elevated only in the serum of naturally infected horses. Previous reports also have consistently demonstrated elevated serum levels of TAGs in both experimental and clinically unresolved immune activation [12–15,36], including human leptospirosis [13]. The mechanism involved in immune-dependent hypertriglyceridemia is thought to involve cytokine activation of triglyceride synthesis in the liver [11]. In contrast, DAGs were elevated in both infected and vaccinated cohorts, suggesting that the synthesis or metabolism of these neutral lipids is altered in both resolved and unresolved immune activation. This is the first report of these changes in DAG levels with immune activation. In this regard, the reports of increased expression of PLD [45, 46] during the early phase of infections suggest that this immune-activated mechanism may be involved in the generation of increased levels of DAGs from glycerophospholipids since PLD metabolizes glycerophospholipids to phosphatidic acids, the direct precursors of DAGs [23].

In our study, sphingomyelins were increased only in the serum of vaccinated horses. Sphingomyelin levels have previously been shown to be elevated in patients with pneumonia [37], and melioidosis [53] while they are unaltered in several bacteremic conditions [53] and

decreased in AIDS patients [38]. Our data indicate that the immune response induced by vaccination has a more dramatic effect than leptospiral infection on sphingomyelin synthesis in horses. The role of these lipids in the immune response remains to be more clearly defined.

In summary, our results provide important information about differences in serum lipids of naturally infected and *Leptospira*-vaccinated horses. Since this study utilized diagnostic and clinical samples, a more controlled, time-matched study is required to further ascertain usefulness of the candidate lipids in differentiating vaccine from infection responses to *Leptospira* spp.

Supporting information

S1 Table.
(XLSX)

Acknowledgments

Funds for this work were provided by LMU-College of Veterinary Medicine's internal grant program. We thank Brittney Beigel, Dan Kish, Joey Morgan, Charles Faulkner, John Dascanio for technical assistance or helpful comments on the manuscript.

Author Contributions

Conceptualization: Paul L. Wood, Ashutosh Verma.

Data curation: Paul L. Wood, Margaret Steinman, Erdal Erol, Craig Carter, Undine Christmann, Ashutosh Verma.

Formal analysis: Paul L. Wood.

Investigation: Paul L. Wood.

Methodology: Paul L. Wood, Ashutosh Verma.

Project administration: Paul L. Wood.

Resources: Paul L. Wood, Margaret Steinman, Erdal Erol, Craig Carter, Undine Christmann, Ashutosh Verma.

Software: Paul L. Wood.

Supervision: Paul L. Wood.

Validation: Paul L. Wood.

Writing – original draft: Paul L. Wood.

Writing – review & editing: Paul L. Wood, Margaret Steinman, Erdal Erol, Craig Carter, Undine Christmann, Ashutosh Verma.

References

1. Adler B, de la Pena Moctezuma A. *Leptospira* and leptospirosis. *Vet. Microbiol.* 2010; 140:287–296. <https://doi.org/10.1016/j.vetmic.2009.03.012> PMID: 19345023.
2. Timoney J F, Kalimthusamy N, Velineni S, Donahue J M, Artiushin S C, Fetting M. A unique genotype of *Leptospira interrogans* serovar Pomona type kennewicki is associated with equine abortion. *Vet Microbiol.* 2011; 150: 349–353. <https://doi.org/10.1016/j.vetmic.2011.02.049> PMID: 21450416
3. Donahue J M, Smith B J, Poonacha K B, Donahoe J K, Rigsby C L. Prevalence and serovars of *Leptospira* involved in equine abortions in central Kentucky during the 1991–1993 foaling seasons. *J. Vet. Diagn. Invest.* 1995; 7:87–91. <https://doi.org/10.1177/104063879500700114> PMID: 7779971

4. Verma A, Stevenson B, Adler B. Leptospirosis in horses. *Veterinary Microbiology* 2013; 167: 61–66. <https://doi.org/10.1016/j.vetmic.2013.04.012> PMID: 23647816.
5. Verma A, Stevenson B. Leptospiral uveitis- there is more to it than meets the eye! *Zoonoses Public Health*, 2012; 59 (Suppl. 2) 132–141.
6. Carter C N, Cohen N, Steinman M N, Smith J L, Erol E, Brown S. Seroepidemiology of equine leptospirosis utilizing diagnostic laboratory specimens from 29 states (US) and one Canadian province. *Proceedings of 55th Annual AAVLD Meet*; p51.
7. Cole J R Jr, Sulzer C R, Pursell A R. Improved microtechnique for the leptospiral microscopic agglutination test. *Appl Microbiol.* 1973; 25(6):976–980. PMID: 4736794
8. Artushin S C, Timoney J F, Nally J, Verma A. Host-inducible immunogenic sphingomyelinase-like protein, Lk73.5, of *Leptospira interrogans*. *Infect. Immun.* 2004; 72:742–749. <https://doi.org/10.1128/IAI.72.2.742-749.2004> PMID: 14742516
9. Verma A, Hellwage J, Artiushin S C, Zipfel P, Kraiczy P, Timoney J F, et al. LfhA, a novel factor H binding protein of *Leptospira interrogans*. *Infect. Immun.* 2006; 74: 2659–2666. <https://doi.org/10.1128/IAI.74.5.2659-2666.2006> PMID: 16622202
10. Palaniappan R U, Chang Y F, Jusuf S S, Artiushin S, Timoney J F, McDonough S P, et al. Cloning and molecular characterization of an immunogenic LigA protein of *Leptospira interrogans*. *Infect Immun.* 2002; 70(11):5924–5930. <https://doi.org/10.1128/IAI.70.11.5924-5930.2002> PMID: 12379666
11. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. *J Lipid Res.* 2004; 45:1169–96. <https://doi.org/10.1194/jlr.R300019-JLR200> PMID: 15102878.
12. Grunfeld C, Feingold KR. Tumor necrosis factor, cytokines, and the hyperlipidemia of infection. *Trends Endocrinol Metab.* 1991; 2:213–9. PMID: 18411185
13. Gazi IF, Apostolou FA, Liberopoulos EN, Filippatos TD, Tellis CC, Elisaf MS, et al. Leptospirosis is associated with markedly increased triglycerides and small dense low-density lipoprotein and decreased high-density lipoprotein. *Lipids.* 2011; 46:953–60. <https://doi.org/10.1007/s11745-011-3580-y> PMID: 21688175.
14. Liberopoulos EN, Apostolou F, Gazi IF, Kostara C, Bairaktari ET, Tselepis AD, et al. Visceral leishmaniasis is associated with marked changes in serum lipid profile. *Eur J Clin Invest.* 2014; 44:719–27. <https://doi.org/10.1111/eci.12288> PMID: 24920396
15. Lamour SD, Gomez-Romero M, Vorkas PA, Alibu VP, Saric J, Holmes E, et al. Discovery of Infection Associated Metabolic Markers in Human African Trypanosomiasis. *PLoS Negl Trop Dis.* 2015; 9: e0004200. <https://doi.org/10.1371/journal.pntd.0004200> PMID: 26505639. Increased TAG and decreased SM
16. Wood PL, Scoggin K, Ball BA, Troedsson MH, Squires EL. Lipidomics of equine sperm and seminal serum: Identification of amphiphilic (O-acyl)- ω -hydroxy-fatty acids. *Theriogenology.* 2016; 86:1212–21. <https://doi.org/10.1016/j.theriogenology.2016.04.012> PMID: 27180330.
17. Wood PL, Barnette BL, Kaye JA, Quinn JF, Woltjer RL. Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimer's disease subjects. *Acta Neuropsychiatr.* 2015; 27:270–8. <https://doi.org/10.1017/neu.2015.18> PMID: 25858158.
18. Wood PL. Non-targeted lipidomics utilizing constant infusion high resolution ESI mass spectrometry. In *Springer Protocols, Neuromethods: Lipidomics 2017*; 125: 13–19. Wood PL (ed). ISSN 0893-2336 and ISSN 1940-6045 (electronic).
19. Vernel-Pauillac F, Merien F. Proinflammatory and immunomodulatory cytokine mRNA time course profiles in hamsters infected with a virulent variant of *Leptospira interrogans*. *Infect Immun.* 2006; 74:4172–9. <https://doi.org/10.1128/IAI.00447-06> PMID: 16790792
20. Naiman BM, Alt D, Bolin CA, Zuerner R, Baldwin CL. Protective killed *Leptospira borgpetersenii* vaccine induces potent Th1 immunity comprising responses by CD4 and gammadelta T lymphocytes. *Infect Immun.* 2001; 69:7550–8. <https://doi.org/10.1128/IAI.69.12.7550-7558.2001> PMID: 11705932
21. Zuerner RL, Alt DP, Palmer MV, Thacker TC, Olsen SC. A *Leptospira borgpetersenii* serovar Hardjo vaccine induces a Th1 response, activates NK cells, and reduces renal colonization. *Clin Vaccine Immunol.* 2011; 18:684–91. <https://doi.org/10.1128/CAI.00288-10> PMID: 21288995
22. Tsukahara T, Tsukahara R, Fujiwara Y, Yue J, Cheng Y, Guo H, et al. Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPAR γ by cyclicphosphatidic acid. *Mol Cell.* 2010; 39:421–32. <https://doi.org/10.1016/j.molcel.2010.07.022> PMID: 20705243.
23. Wood PL. Lipidomics of Alzheimer's disease: current status. *Alzheimers Res Ther.* 2012; 4:5. <https://doi.org/10.1186/alzrt103> PMID: 22293144.
24. Losito I, Facchini L, Diomede S, Conte E, Megli FM, Cataldi TR, et al. Hydrophilic interaction liquid chromatography-electrospray ionization-tandem mass spectrometry of a complex mixture of native and

- oxidized phospholipids. *J Chromatogr A*. 2015; 1422:194–205. <https://doi.org/10.1016/j.chroma.2015.10.023> PMID: 26508677.
25. Nakagawa K, Kato S, Miyazawa T. Determination of Phosphatidylcholine Hydroperoxide (PCOOH) as a Marker of Membrane Lipid Peroxidation. *J Nutr Sci Vitaminol (Tokyo)*. 2015; 61 Suppl:S78–80. <https://doi.org/10.3177/jnsv.61.S78> PMID: 26598897.
 26. Schotthoefer AM, Schrodi SJ, Meece JK, Fritsche TR, Shukla SK. Pro-inflammatory immune responses are associated with clinical signs and symptoms of human anaplasmosis. *PLoS One*. 2017 12: e0179655. <https://doi.org/10.1371/journal.pone.0179655> PMID: 28628633.
 27. Khovichunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. *J Infect Dis*. 2000; 181 Suppl 3:S462–72. <https://doi.org/10.1086/315611> PMID: 10839741.
 28. Avelino-Silva VI, Miyaji KT, Hunt PW, Huang Y, Simoes M, et al. CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients. *PLoS Negl Trop Dis*. 2016; 10: e0005219. <https://doi.org/10.1371/journal.pntd.0005219> PMID: 27941965.
 29. Gomes STM, Gomes ÉR, Dos Santos MB, Lima SS, Queiroz MAF, Machado LFA, et al. Immunological and virological characterization of HIV-1 viremia controllers in the North Region of Brazil. *BMC Infect Dis*. 2017; 17:381. <https://doi.org/10.1186/s12879-017-2491-9> PMID: 28571570.
 30. Cortés A, Muñoz-Antoli C, Esteban JG, Toledo R. Th2 and Th1 Responses: Clear and Hidden Sides of Immunity Against Intestinal Helminths. *Trends Parasitol*. 2017; <https://doi.org/10.1016/j.pt.2017.05.004> PMID: 28566191.
 31. Vitenberga Z, Pilmane M. Inflammatory, anti-inflammatory and regulatory cytokines in relatively healthy lung tissue as an essential part of the local immune system. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*. 2017; 161:164–173. <https://doi.org/10.5507/bp.2017.029> PMID: 28627525.
 32. Wood PL. Roles of CNS macrophages in neurodegeneration. In *Neuroinflammation: Mechanisms and Management*. pg 1–59. Springer Science. Wood PL (ed). ISBN 978-1-4757-5961-7 and ISBN 978-1-59259-473-3 (eBook).
 33. Nemeth ZH, Bogdanovski DA, Barratt-Stopper P, Paglinco SR, Antonioli L, Rolandelli RH. Crohn's Disease and Ulcerative Colitis Show Unique Cytokine Profiles. *Cureus* 2017; 9:e1177. <https://doi.org/10.7759/cureus.1177> PMID: 28533995.
 34. Ait-Belkacem R, Bol V, Hamm G, Schramme F, Van Den Eynde B, Poncelet L, et al. Microenvironment Tumor Metabolic Interactions Highlighted by qMSI: Application to the Tryptophan-Kynurenine Pathway in Immuno-Oncology. *SLAS Discov*. 2017; <https://doi.org/10.1177/2472555217712659> PMID: 28557618.
 35. Braidy N, Grant R. Kynurenine pathway metabolism and neuroinflammatory disease. *Neural Regen Res*. 2017; 12:39–42. <https://doi.org/10.4103/1673-5374.198971> PMID: 28250737.
 36. Wood PL. Differential regulation of IL-1 alpha and TNF alpha release from immortalized murine microglia (BV-2). *Life Sci*. 1994; 55:661–8. PMID: 8065228.
 37. To KK, Lee KC, Wong SS, Sze KH, Ke YH, Lui YM, et al. Lipid metabolites as potential diagnostic and prognostic biomarkers for acute community acquired pneumonia. *Diagn Microbiol Infect Dis*. 2016; 85:249–54. <https://doi.org/10.1016/j.diagmicrobio.2016.03.012> PMID: 27105773
 38. Scarpelini B, Zanoni M, Sucupira MC, Truong HM, Janini LM, Segurado ID, et al. Serum Metabolomics Biosignature According to HIV Stage of Infection, Pace of Disease Progression, Viremia Level and Immunological Response to Treatment. *PLoS One*. 2016; 11:e0161920. <https://doi.org/10.1371/journal.pone.0161920> PMID: 27941971.
 39. Levett PN. Leptospirosis. *Clin. Microbiol. Rev*. 2001; 14:296–326. <https://doi.org/10.1128/CMR.14.2.296-326.2001> PMID: 11292640.
 40. Velineni S, Timoney JF. Preliminary evaluation of a dual antigen ELISA to distinguish vaccinated from *Leptospira* infected horses. *Vet Rec*. 2016; 179:574. <https://doi.org/10.1136/vr.103686> PMID: 27650465.
 41. Spiri AM, Rodriguez-Campos S, Matos JM, Glaus TM, Riond B, Reusch CE, et al. Clinical, serological and echocardiographic examination of healthy field dogs before and after vaccination with a commercial tetravalent leptospirosis vaccine. *BMC Vet Res*. 2017; 13:138. <https://doi.org/10.1186/s12917-017-1056-x> PMID: 28545521.
 42. Christmann U, Buechner-Maxwell V, Witonsky S, Hite D, Wood PL. Levels of cyclic phosphatidic acid are increased in surfactant from asthmatic horses exposed to hay. 34th Annual Symposium of the Veterinary Comparative Respiratory Society, Lansing, Michigan, September 18-21st, 2016.
 43. Jeewandara C, Gomes L, Udari S, Paranavitane SA, Shyamali NL, Ogg GS, et al. Secretory phospholipase A2 in the pathogenesis of acute dengue infection. *Immun Inflamm Dis*. 2016; 5:7–15. <https://doi.org/10.1002/iid3.135> PMID: 28250920.

44. Vijay R, Hua X, Meyerholz DK, Miki Y, Yamamoto K, Gelb M, et al. Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection. *J Exp Med*. 2015; 212:1851–68. <https://doi.org/10.1084/jem.20150632> PMID: 26392224.
45. Brown HA, Thomas PG, Lindsley CW. Targeting phospholipase D in cancer, infection and neurodegenerative disorders. *Nat Rev Drug Discov*. 2017; 16:351–367. <https://doi.org/10.1038/nrd.2016.252> PMID: 28209987.
46. Lucas EA, Billington SJ, Carlson P, McGee DJ, Jost BH. Phospholipase D promotes *Arcanobacterium haemolyticum* adhesion via lipid raft remodeling and host cell death following bacterial invasion. *BMC Microbiol*. 2010; 10:270. <https://doi.org/10.1186/1471-2180-10-270> PMID: 20973961.
47. Fujiwara Y. Cyclic phosphatidic acid—a unique bioactive phospholipid. *Biochim Biophys Acta*. 2008; 1781:519–24. <https://doi.org/10.1016/j.bbalip.2008.05.002> PMID: 18554524.
48. Tsukahara T. PPAR γ Networks in Cell Signaling: Update and Impact of Cyclic Phosphatidic Acid. *J Lipids*. 2013; 2013:246597. <https://doi.org/10.1155/2013/246597> PMID: 23476786.
49. Tsukahara T, Haniu H, Matsuda Y. Cyclic phosphatidic acid inhibits alkyl-glycerophosphate-induced downregulation of histone deacetylase 2 expression and suppresses the inflammatory response in human coronary artery endothelial cells. *Int J Med Sci*. 2014; 11:955–61. <https://doi.org/10.7150/ijms.9316> PMID: 25013374.
50. Gotoh M, Nagano A, Tsukahara R, Murofushi H, Morohoshi T, Otsuka K, et al. Cyclic phosphatidic acid relieves osteoarthritis symptoms. *Mol Pain*. 2014; 10:52. <https://doi.org/10.1186/1744-8069-10-52> PMID: 25123228.
51. Yamamoto S, Gotoh M, Kawamura Y, Yamashina K, Yagishita S, Awaji T, et al. Cyclic phosphatidic acid treatment suppress cuprizone-induced demyelination and motor dysfunction in mice. *Eur J Pharmacol*. 2014; 741:17–24. <https://doi.org/10.1016/j.ejphar.2014.07.040> PMID: 25084219.
52. Tsukahara T, Matsuda Y, Haniu H. Cyclic phosphatidic acid stimulates cAMP production and inhibits growth in human colon cancer cells. *PLoS One*. 2013; 8:e81139. <https://doi.org/10.1371/journal.pone.0081139> PMID: 24282571.
53. Lau SK, Lee KC, Lo GC, Ding VS, Chow WN, Ke TY, et al. Metabolomic Profiling of Serum from Melioidosis Patients Using UHPLC-QTOF MS Reveals Novel Biomarkers for Diagnosis. *Int J Mol Sci*. 2016; 17:307. <https://doi.org/10.3390/ijms17030307> PMID: 26927094.